Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent antigen detection by immunofluorescent technique; Rubeola

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87283 refers to a laboratory test specifically designed for the detection of the rubeola virus antigen using an immunofluorescent technique. This test is crucial for identifying the presence of the rubeola virus, which is responsible for measles, a highly contagious viral infection characterized by respiratory symptoms and a distinctive rash. The rubeola virus is a single-stranded, enveloped RNA virus with only one serotype, making it unique in its classification. The procedure involves collecting samples from the patient, which may include nasal or pharyngeal swabs, aspirates, urine, or serum. The immunofluorescent technique employed in this test utilizes specific antibodies that bind to the rubeola virus antigens present in the sample. When these antibodies are applied to the sample and examined under an epifluorescence microscope, any binding will result in a visible color change, indicating the presence of the virus. This method is noted for its rapid results, although it may be less sensitive compared to other testing methods such as reverse transcription-polymerase chain reaction (RT-PCR). Understanding the implications of this test is essential for timely diagnosis and management of measles, especially considering the contagious nature of the virus and the potential for outbreaks in unvaccinated populations.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87283 is indicated for the detection of the rubeola virus antigen in patients who present with symptoms consistent with measles. The following conditions warrant the performance of this test:

  • Measles Symptoms Patients exhibiting high fever, malaise, cough, coryza, and conjunctivitis, which are characteristic symptoms of measles.
  • Koplik Spots The presence of early Koplik spots on the oral mucosa, which are indicative of measles infection.
  • Rash Development Individuals who develop a maculopapular rash that typically spreads from the head to the feet, appearing approximately 14 days after exposure to the virus.
  • Contagious Period Individuals who have been in contact with a confirmed measles case, especially during the contagious period, which is 4 days prior to and 4 days after the appearance of the rash.

2. Procedure

The procedure for performing the test under CPT® Code 87283 involves several critical steps to ensure accurate detection of the rubeola virus antigen:

  • Sample Collection A respiratory sample, such as a nasal or pharyngeal swab or aspirate, or a urine or serum sample is collected from the patient. This sample serves as the basis for the antigen detection.
  • Reagent Treatment The collected sample is treated with a detecting reagent that contains specific antibodies against the rubeola virus. This reagent is designed to bind to any rubeola virus antigens present in the sample.
  • Counterstaining A counterstain is applied to the sample to enhance visualization under the microscope. This step is crucial for distinguishing between bound and unbound antibodies during examination.
  • Microscopic Examination The treated sample is then examined under an epifluorescence microscope. The presence of rubeola virus antigens will result in a distinct color change due to the binding of the antibodies to the antigens.

3. Post-Procedure

After the procedure, the results of the test will be analyzed and reported. It is important to note that while the immunofluorescent technique provides rapid results, it may be less sensitive than other methods such as reverse transcription-polymerase chain reaction (RT-PCR). Therefore, if the test result is negative but clinical suspicion remains high, further testing may be warranted. Additionally, healthcare providers should consider the patient's clinical history and symptoms when interpreting the results. Proper follow-up care and monitoring for any potential complications associated with measles should be conducted, especially in cases where the patient is confirmed to have the virus.

Short Descr RUBEOLA AG IF
Medium Descr IAADI RUBEOLA
Long Descr Infectious agent antigen detection by immunofluorescent technique; Rubeola
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
Date
Action
Notes
2011-01-01 Changed Short description changed.
2001-01-01 Added First appearance in code book in 2001.
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"